Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials

REFERENCES

1. 1.↵
   1. Gautret P,
   2. Lagier JC,
   3. Parola P,
   4. et al.

   Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949

   OpenUrlCrossRefPubMed
2. 2.
   1. Rosendaal FR

   . Review of: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. Int J Antimicrob Agents. 2020;56(1):106063. doi: 10.1016/j.ijantimicag.2020.106063

   OpenUrlCrossRef
3. 3.↵
   1. Voss A,
   2. Coombs G,
   3. Unal S,
   4. Saginur R,
   5. Hsueh PR

   . Publishing in face of the COVID-19 pandemic. Int J Antimicrob Agents. 2020;56(1):106081. doi: 10.1016/j.ijantimicag.2020.106081

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Chen J,
   2. Liu D,
   3. Liu L,
   4. et al.

   A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215-219.

   OpenUrlPubMed
5. 5.↵
   1. Chen Z,
   2. Hu J,
   3. Zhang Z,
   4. et al.

   Efficacy of hydroxychloroquine in patients with Covid-19: results of a randomized clinical trial. medRxiv. Preprint posted online April 10, 2020. doi: 10.1101/2020.03.22.20040758

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Boulware DR,
   2. Pullen MF,
   3. Bangdiwala AS,
   4. et al.

   A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525. doi: 10.1056/NEJMoa2016638

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Cavalcanti AB,
   2. Zampieri FG,
   3. Rosa RG

   , et al; Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041-2052. doi: 10.1056/NEJMoa2019014

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Chen L,
   2. Zhang Z,
   3. Fu J,
   4. et al.

   Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of Covid-19: a prospective open-label randomized study. medRxiv. Preprint posted online June 22, 2020. doi: 10.1101/2020.06.19.20136093

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Tang W,
   2. Cao Z,
   3. Han M,
   4. et al.

   Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv. Preprint posted online May 7, 2020. doi: 10.1101/2020.04.10.20060558

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Chen CP,
    2. Lin YC,
    3. Chen TC,
    4. et al.

    A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adults with mild to moderate Coronavirus disease 2019 (COVID-19). medRxiv. Preprint posted online July 10, 2020. doi: 10.1101/2020.07.08.20148841
11. 11.↵
    1. Borba MGS,
    2. Val FFA,
    3. Sampaio VS

    , et al; CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857

    OpenUrlCrossRef
12. 12.↵
    1. Mitjà O,
    2. Corbacho-Monné M,
    3. Ubals M

    , et al; BCN PEP-CoV-2 Research Group. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clin Infect Dis. 2020;ciaa1009. doi: 10.1093/cid/ciaa1009

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Skipper CP,
    2. Pastick KA,
    3. Engen NW,
    4. et al.

    Hydroxychloroquine in nonhospitalized adults with early Covid-19: a randomized trial. Ann Intern Med. 2020;173(8):623-631. doi: 10.7326/M20-4207

    OpenUrlCrossRefPubMed